Resources invested globally in the field of global health Research & Development (R&D) for biomedical innovations such as drugs, vaccines and diagnostics to tackle diseases have been limited and in many neglected disease areas are now stagnant. Investments in global health R&D are instrumental for accelerating and sustaining global health R&D pipelines. With adequate funding and a systematic prioritization, global health R&D has the potential to deliver appropriate R&D products targeting low and middle income country populations, contributing to the alleviation of morbidity and socioeconomic burden among the world’s poor. In the absence of systematic priority setting, there is a risk of misallocation of valuable, yet scarce, resources in global health R&D.
i4C-6 and i4C-7 projects aim to review current approaches to pharmaceutical R&D priority setting and their relevance to global health R&D as well as critically examine how they relate and differ, how they can complement each other, and how their usefulness varies across contextual factors and stages in the global health R&D funding flow chain. Against this review, the projects aim to develop and to test new methodologiesfor the systematic prioritization of global health R&D investments, by applying multi-criteria decision analysis and combinatorial optimization techniques. The projects aim to ultimately assess whether a ‘multi-criteria value-maximization’ tool can be applied for the prioritization of investments in global health R&D, recognizing the existence of multiple objectives and variable preferences between organizations responsible for funding, managing and conducting R&D across different sectors, national income and geographical clusters.